Northpointe Capital’s MacroGenics MGNX Stock Holding History

Northpointe Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-57,264	Closed	-$1.44M	–	181
2018 Q1	$1.44M	Buy	+57,264	New	+$1.39M	0.18%	157

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Northpointe Capital's MGNX Position: Q2 2018 in Review

Northpointe Capital sold out of MacroGenics (MGNX) in Q2 2018, closing a stake of 57,264 shares — an estimated $1.44M sold.

Northpointe Capital first reported a position in MGNX in Q1 2018 and held it in 1 quarter. The position peaked at $1.44M in Q1 2018. 127 funds tracked by Wall St. Rank hold MGNX as of Q2 2018.

Northpointe Capital reported no remaining MacroGenics position as of Q2 2018 after selling out during the quarter.
Northpointe Capital sold 57,264 MacroGenics shares in Q2 2018, an estimated $1.44M.
Northpointe Capital first reported a position in MacroGenics in Q1 2018 and held it in 1 quarter.
Northpointe Capital's MacroGenics position peaked at $1.44M in Q1 2018.
127 funds tracked by Wall St. Rank held MacroGenics as of Q2 2018.

Based on Northpointe Capital's 13F filing for Q2 2018, filed 25 Jul 2018.